My Profile

Search abstracts

Lewis Sheiner


2020
Ljubljana, Slovenia



2019
Stockholm, Sweden

2018
Montreux, Switzerland

2017
Budapest, Hungary

2016
Lisboa, Portugal

2015
Hersonissos, Crete, Greece

2014
Alicante, Spain

2013
Glasgow, Scotland

2012
Venice, Italy

2011
Athens, Greece

2010
Berlin, Germany

2009
St. Petersburg, Russia

2008
Marseille, France

2007
KÝbenhavn, Denmark

2006
Brugge/Bruges, Belgium

2005
Pamplona, Spain

2004
Uppsala, Sweden

2003
Verona, Italy

2002
Paris, France

2001
Basel, Switzerland

2000
Salamanca, Spain

1999
Saintes, France

1998
Wuppertal, Germany

1997
Glasgow, Scotland

1996
Sandwich, UK

1995
Frankfurt, Germany

1994
Greenford, UK

1993
Paris, France

1992
Basel, Switzerland



Printable version

PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe.
ISSN 1871-6032

Reference:
PAGE 26 (2017) Abstr 7151 [www.page-meeting.org/?abstract=7151]


Poster: Drug/Disease modelling - Other topics


II-28 Valentina Topic Vucenovic Nonlinear mixed effects modelling approach for investigation of 131I kinetics in patients with benign thyroid disease

Valentina Topic Vucenovic (1), Katarina Vucicevic (1), Zvezdana Rajkovaca (2), Dragi Stanimirovic (2), Goran Vuleta (2), Dijana Jelic (3), Branislava Miljkovic (1)

(1) Department of Pharmacokinetics and Clinical Pharmacy, University of Belgrade - Faculty of Pharmacy, Serbia, (2) Institute of Nuclear Medicine and Thyroid Gland Disease, University Clinical Centre of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina, (3) Faculty of Medicine, University of Banja Luka, Bosnia and Herzegovina

Objectives: Radioiodine therapy is a common approach in the treatment of benign thyroid diseases. The aim of the study was to investigate factors that influence intrathyroidal kinetics of 131I in patients with benign thyroid disease and to develop population kinetic model using routine clinical data on radioiodine uptake measurement following administration of the tracer activity.

Methods: Demographic and clinical characteristics of patients with benign thyroid disease were retrospectively collected from patients' medical records. Uptake of radioiodine in thyroid (RIU(t)) was measured 4, 24, 48 h, and in some patients 168 h following oral administration of a capsule with nominal test activity of 1.85 MBq of 131I. Population analysis was performed using NONMEM® software (v7.3) and PsN® (v4.6.0). Following covariates were tested: gender, age, diagnosis, functional thyroid volume, presence of cardiovascular disease, thyroid-stimulating hormone (TSH), free thyroxine (fT4), previous therapy with anti-thyroid drugs (ATDs) and therapy discontinuation time before administration of the test activity.

Results: In total 366 adult patients, and 899 uptake measurements were included in the analysis.  The two-compartment model of 131I biokinetics was used as the structural model [1]. The interindividual variability (IIV) of the rate constant of the uptake of radioiodine in the thyroid (ktu) was described by an exponential model, while the residual error was best described by a proportional model. Results of the study indicate that ktu in patients with benign thyroid disease is significantly influenced by diagnosis, age, functional thyroid volume, fT4 in plasma, use of ATDs and time of discontinuation of therapy. According to the final model, effective half-life of 131I in typical patient is 6.56 days, and for each additional year it increases on average by 3.95%. Inclusion of the covariates in the base model resulted in decrease of the IIV for  ktu from 89.8% (7.6%) to 55.6% (4.5%) with shrinkage of 3.9%. Acceptable performances of the final model were confirmed by nonparametric bootstrap analysis and predictive checks.

Conclusion: The developed population kinetic model of 131I explained significant portion of interindividual variability in 131I intrathyroidal kinetics and can be used for estimation of individual time-integrated activity coefficient of 131I needed for patient specific calculation of therapeutic activity for radioiodine therapy of benign thyroid diseases.



References:
[1] Hanscheid H, Lassmann M, Reiners C. Dosimetry prior to I-131-therapy of benign thyroid disease. Zeitschrift fur medizinische Physik (2011) 21:250-7.